( DrugBank: - / KEGG DRUG: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 62 | Paroxysmal nocturnal hemoglobinuria | 292 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 275 |
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108
Showing 1 to 10 of 292 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05731050 (ClinicalTrials.gov) | June 202520250600 | 1/2/202320230201 | Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Noctu ... | PNH - Paroxysmal Nocturnal Hemoglobinuria | Drug: NM8074 | NovelMed Therapeutics | NULL | Not yet recruiting | 18 Years | 65 Years | All | 6 | Phase 2 | NULL |
| 2 | NCT05646524 (ClinicalTrials.gov) | November 202320231100 | 30/11/202220221130 | Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor T ... | A Phase II, Open-Label Study of NM8074 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria | Drug: NM8074 | NovelMed Therapeutics | NULL | Not yet recruiting | 18 Years | N/A | All | 12 | Phase 2 | NULL |
| 3 | NCT05646563 (ClinicalTrials.gov) | September 202320230900 | 30/11/202220221130 | Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris | A Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) A Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemogl ... | Paroxysmal Nocturnal Hemoglobinuria | Drug: NM8074;Drug: Soliris | NovelMed Therapeutics | NULL | Not yet recruiting | 18 Years | N/A | All | 12 | Phase 2 | NULL |
| 4 | NCT05630001 (ClinicalTrials.gov) | May 30, 202320230530 | 18/11/202220221118 | This is a Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. This is a Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable ... | A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb=10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Ipt ... | Paroxysmal Nocturnal Hemoglobinuria | Drug: Iptacopan | Novartis Pharmaceuticals | NULL | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 3 | NULL |
| 5 | NCT05744921 (ClinicalTrials.gov) | March 9, 202320230309 | 6/2/202320230206 | A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran ... | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozeli ... | Paroxysmal Nocturnal Hemoglobinuria | Drug: Pozelimab;Drug: Cemdisiran | Regeneron Pharmaceuticals | NULL | Not yet recruiting | 18 Years | N/A | All | 300 | Phase 3 | NULL |
| 6 | EUCTR2021-004253-22-GR (EUCTR) | 23/01/202320230123 | 29/11/202220221129 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. ... | A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated with Danicopan in an Alexion-sponsored Clinical Study. A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on ... | Patients with Paroxysmal Nocturnal Hemoglobinuria <br>MedDRA version: 21.1;Level: PT;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Patients with Paroxysmal Nocturnal Hemoglobinuria <br>MedDRA version: 21.1;Level: PT;Classification ... | Product Name: Danicopan<br>Product Code: ALXN2040<br>INN or Proposed INN: DANICOPAN<br>Other descriptive name: DANICOPAN<br>Product Name: Danicopan<br>Product Code: ALXN2040<br>INN or Proposed INN: DANICOPAN<br>Other descriptive name: DANICOPAN Product Name: Danicopan<br>Product Code: ALXN2040<br>INN or Proposed INN: DANICOPAN<br>Other descrip ... | Alexion Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 95 | Phase 3 | United States;Czechia;Greece;Thailand;Spain;Israel;United Kingdom;Italy;France;Canada;Brazil;Malaysia;Poland;Japan;Korea, Republic of United States;Czechia;Greece;Thailand;Spain;Israel;United Kingdom;Italy;France;Canada;Brazil;Malaysi ... | ||
| 7 | NCT05741346 (ClinicalTrials.gov) | January 18, 202320230118 | 14/2/202320230214 | Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria | An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst-sponsored Study An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxys ... | Paroxysmal Nocturnal Hemoglobinuria | Drug: BCX9930 | BioCryst Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Hungary;Malaysia |
| 8 | EUCTR2021-004931-10-GR (EUCTR) | 04/01/202320230104 | 22/11/202220221122 | A study to examine the long-term safety, tolerability, and effectiveness of Pozelimab and Cemdisiran combination therapy in adult patients with Paroxysmal Nocturnal Hemoglobinuria A study to examine the long-term safety, tolerability, and effectiveness of Pozelimab and Cemdisiran ... | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria - ACCESS-EXTENSION An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozeli ... | Paroxysmal nocturnal hemoglobinuria (PNH) <br>MedDRA version: 21.1;Level: LLT;Classification code 10055629;Term: Paroxysmal nocturnal hemoglobinuria;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Paroxysmal nocturnal hemoglobinuria (PNH) <br>MedDRA version: 21.1;Level: LLT;Classification code 10 ... | Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab<br>Product Name: Cemdisiran<br>Product Code: ALN-CC5<br>INN or Proposed INN: Cemdisiran<br>Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab<br>Product Name: ... | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 288 | Phase 3 | United States;Philippines;Taiwan;Greece;Thailand;Spain;Colombia;Italy;India;France;Jordan;Malaysia;Peru;South Africa;China;Korea, Democratic People's Republic of;Turkey;United Kingdom;Hungary;Mexico;Canada;Brazil;Poland;Singapore;Romania;Germany;Japan United States;Philippines;Taiwan;Greece;Thailand;Spain;Colombia;Italy;India;France;Jordan;Malaysia;P ... | ||
| 9 | EUCTR2020-002761-33-FR (EUCTR) | 06/12/202220221206 | 21/03/202220220321 | Efficacy and Safety of the Combination of Pozelimab and Cemdisiran versus continued Eculizumab or Ravulizumab Treatment in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Efficacy and Safety of the Combination of Pozelimab and Cemdisiran versus continued Eculizumab or Ra ... | A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE CURRENTLY TREATED WITH ECULIZUMAB OR RAVULIZUMAB A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SA ... | Paroxysmal nocturnal hemoglobinuria (PNH) <br>MedDRA version: 21.1;Level: LLT;Classification code 10055629;Term: Paroxysmal nocturnal hemoglobinuria;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Paroxysmal nocturnal hemoglobinuria (PNH) <br>MedDRA version: 21.1;Level: LLT;Classification code 10 ... | Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab<br>Product Name: Cemdisiran<br>Product Code: ALN-CC5<br>INN or Proposed INN: CEMDISIRAN<br>Other descriptive name: CEMDISIRAN<br>Trade Name: ULTOMIRIS ™ (ravulizumab-cwvz)<br>INN or Proposed INN: Ravulizumab<br>Other descriptive name: Ravulizumab<br>Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab<br>Trade Name: Soliris ™ (eculizumab)<br>Product Name: Eculizumab<br>INN or Proposed INN: Eculizumab Product Name: Pozelimab<br>Product Code: REGN3918<br>INN or Proposed INN: Pozelimab<br>Product Name: ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes<br>Male: yes | 140 | Phase 3 | Portugal;United States;Philippines;Taiwan;Greece;Spain;Turkey;Colombia;United Kingdom;Italy;France;Mexico;Poland;Brazil;Singapore;Romania;Netherlands;Germany;Japan;Korea, Republic of Portugal;United States;Philippines;Taiwan;Greece;Spain;Turkey;Colombia;United Kingdom;Italy;France;M ... | ||
| 10 | NCT05476887 (ClinicalTrials.gov) | November 25, 202220221125 | 25/7/202220220725 | To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 | An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-naïve Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic ... | Paroxysmal Nocturnal Hemoglobinuria | Drug: KP104 | Kira Pharmacenticals (US), LLC. | NULL | Recruiting | 18 Years | N/A | All | 35 | Phase 2 | China |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
Showing 1 to 10 of 275 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05517980 (ClinicalTrials.gov) | July 1, 202320230701 | 24/8/202220220824 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis | An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ... | Glomerulonephritis | Drug: KP104 | Kira Pharmacenticals (US), LLC. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 52 | Phase 2 | NULL |
| 2 | NCT05687890 (ClinicalTrials.gov) | April 202320230400 | 9/1/202320230109 | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to In ... | Diabetic Kidney Disease;IgA Nephropathy | Drug: Placebo of SC0062;Drug: SC0062 low dose;Drug: SC0062 medium dose;Drug: SC0062 high dose | Biocity Biopharmaceutics Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 240 | Phase 2 | NULL |
| 3 | NCT05596708 (ClinicalTrials.gov) | March 1, 202320230301 | 25/10/202220221025 | Study of Telitacicept in Patients With Refractory IgA Nephropathy | A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractory IgA Nephropathy A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractor ... | IgA Nephropathy | Drug: Telitacicept | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 40 | Phase 2/Phase 3 | China |
| 4 | NCT05174221 (ClinicalTrials.gov) | November 9, 202220221109 | 14/12/202120211214 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgrou ... | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ... | Kidney Disease | Drug: Mezagitamab | Takeda | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain; ... |
| 5 | EUCTR2020-005855-19-HU (EUCTR) | 03/11/202220221103 | 08/04/202220220408 | Evaluating oral BCX9930 in renal diseases | An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy - RENEW An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects ... | complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy <br>MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders <br>MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders <br>MedDRA version: 20.0;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy <br>MedDRA ver ... | Product Name: BCX9930<br>Product Code: BCX9930<br>INN or Proposed INN: BCX9930<br>Other descriptive name: BCX9930 hydrochloride<br>Product Name: BCX9930<br>Product Code: BCX9930<br>INN or Proposed INN: BCX9930<br>Other descriptive name: BCX9930 hydrochloride Product Name: BCX9930<br>Product Code: BCX9930<br>INN or Proposed INN: BCX9930<br>Other descriptive ... | BioCryst Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes<br>Male: yes | 42 | Phase 2 | France;Hungary;Spain;Romania;Germany;United Kingdom;Italy | ||
| 6 | NCT05534919 (ClinicalTrials.gov) | September 202220220900 | 6/9/202220220906 | Efficacy and Safety in Chinese Patients With Immunoglobulin A Nephropathy (IgAN) Who Have Completed Study Nef-301 Efficacy and Safety in Chinese Patients With Immunoglobulin A Nephropathy (IgAN) Who Have Completed ... | An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Ompleted Study Nef-301 in China An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Pati ... | Primary Immunoglobulin A Nephropathy (IgAN) | Drug: Nefecon | Everest Medicines (Singapore) Pte. Ltd. | NULL | Not yet recruiting | 18 Years | N/A | All | 58 | Phase 3 | China |
| 7 | NCT05383547 (ClinicalTrials.gov) | August 2, 202220220802 | 10/5/202220220510 | Bortezomib for Treating Glomerular Diseases | Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases | Bortezomib;Glomerulonephritis;MN;MPGN;FSGS;IgA Nephropathy | Drug: Bortezomib | Ruijin Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | N/A | China |
| 8 | ITMCTR2200006488 | 2022-08-0120220801 | 2022-08-1520220815 | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 A clinical study of traditional Chinese medicine combined with western medicine in treatment of prim ... | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 A clinical study of traditional Chinese medicine combined with western medicine in treatment of prim ... | IgA nephropathy | Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 prescription; Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 ... | Shanghai east hospital (East Hospital affiliated to Tongji University) | NULL | Pending | 18 | 75 | Both | Valsartan:42;group combination of Chinese and Western medicine:21; | China | |
| 9 | JPRN-jRCT2011220009 | 17/07/202220220717 | 15/06/202220220615 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgrou ... | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ... | Kidney Disease | TAK-079 (Mezagitamab)<br>Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period. TAK-079 (Mezagitamab)<br>Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once ever ... | Nishizawa Atsushi | NULL | Recruiting | >= 18age old | Not applicable | Both | 16 | Phase 1 | Australia;China;Spain;Italy;South Korea;Serbia;Singapore;Taiwan;USA;Belgium;Hungary;UK;Japan |
| 10 | EUCTR2020-001049-38-SK (EUCTR) | 08/07/202220220708 | 31/05/202220220531 | Study of efficacy and safety of LNP023 in primary IgA nephropathy patients | A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to eva ... | IgA Nephropathy <br>MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA Nephropathy <br>MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropath ... | Product Name: iptacopan<br>Product Code: LNP023<br>INN or Proposed INN: iptacopan<br>Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Name: iptacopan<br>Product Code: LNP023<br>INN or Proposed INN: iptacopan<br>Other descripti ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes<br>Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Thailand;Spain;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Malaysia;Viet Nam;Denmark;Australia;South Africa;Netherlands;China;Korea, Republic of;Czechia;Slovenia;Finland;Turkey;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Singapore;Norway;Germany;Japan;Sweden United States;Taiwan;Slovakia;Thailand;Spain;Russian Federation;Israel;Chile;Colombia;Italy;India;Fr ... |